top of page

A review of neurological side effects of COVID-19 vaccination

Roya Hosseini & Nayere Askari

European Journal of Medical Research volume 28, Article number: 102 (2023)


Following the COVID-19 virus epidemic, extensive, coordinated international research has led to the rapid development of effective vaccines. Although vaccines are now considered the best way to achieve collective safety and control mortality, due to the critical situation, these vaccines have been issued the emergency use licenses and some of their potential subsequence side effects have been overlooked. At the same time, there are many reports of side effects after getting a COVID-19 vaccine. According to these reports, vaccination can have an adverse event, especially on nervous system. The most important and common complications are cerebrovascular disorders including cerebral venous sinus thrombosis, transient ischemic attack, intracerebral hemorrhage, ischemic stroke, and demyelinating disorders including transverse myelitis, first manifestation of MS, and neuromyelitis optica. These effects are often acute and transient, but they can be severe and even fatal in a few cases. Herein, we have provided a comprehensive review of documents reporting neurological side effects of COVID-19 vaccines in international databases from 2020 to 2022 and discussed neurological disorders possibly caused by vaccination.


In December 2019, the SARS Covid-2 virus was introduced to the world. A virus that was much more contagious than SARS Covid-1 and spread to different parts of the world in a short time. Following that situation in 2020, the World Health Organization had to declare a global health emergency. This virus is known to cause widespread lung infection and hypoxia [1]. As of November 2022, 630.3 million people have been diagnosed with COVID-19 and 6.58 million deaths worldwide, according to WHO figures [2].

In early 2021, the first vaccines were introduced to stop the pandemic. Also, approximately 68.2% of the world's population has been fully vaccinated against this disease. There are four major strategies for producing COVID-19 vaccines, including nucleic acid-based vaccine (DNA–mRNA), viral vector (replication–non-replication), live inactivated (or attenuated) virus, and protein (spike protein or its subunits). In nucleic acid and adenovirus-based vaccines, fragments of the virus mRNA or genome enter human cells and induce the production of viral proteins [3]. These viral proteins are eventually identified as antigens and stimulate antibody production. In vaccines containing inactive or protein viruses, virus particles and proteins, as antigens, trigger the immune system [4]. As of November 2021, 11 candidate vaccines for COVID-19 have been approved by the World Health Organization for mass vaccination after leaving phase 3 of clinical studies. However, in order to prove the effectiveness of the vaccine in terms of safety and side effects, the implementation of phase 4 of clinical studies is necessary. Because the results of the phase 4 studies are the proper criteria for how the vaccine works in the real world [5].

Vaccines have always been known to be the most effective and safest drugs; however, different side effects have been identified for them, for example, the link between influenza, hepatitis, and HPV vaccines with demyelinating syndromes has been discovered, and the injection of influenza vaccine is a reason for the incidence of narcolepsy in young people [6].

Because COVID-19 vaccines are urgently approved, meaning they do not complete the standard clinical trials, the adverse effects of each vaccine should be closely monitored. It is necessary to pay attention to the fact that in mass vaccination, due to different races, disease history, age, lifestyle, and other effective factors, the incidence of adverse effects of vaccination is higher. According to data from the CDC, VAERS, and EMA databases, the short-term outcome of COVID-19 vaccination is promising, but in the medium and long term, especially with some vaccines, side effects have been reported that are worrisome. VST is the most severe disorder that should be diagnosed and controlled immediately. Therefore, physicians and personnel of medical centers related to these patients should recognize these complications and intervene as soon as possible.

Search method

Research, Review, and Case Report articles related to adverse effects of COVID-19 vaccination from 2020 to February 2022 were searched and reviewed in Google Scholar, PubMed, and NCBI databases. Many Case Report articles were not considered due to the lack of a convincing link between the complication and vaccination. Keywords used for this search included COVID-19, SARS-CoV-2, vaccination, side effects, complications, vascular thrombosis, thrombocytopenia, myelitis, demyelination, and all kind of mRNA vaccines, Adenovirus vaccine, Pfizer, AstraZeneca, Johnson & Johnson, Moderna, Sinovac, Sinopharm, Sputnik, and Covaxin. For ease of understanding the various side effects of COVID-19 vaccination, the main categories are shown in Fig. 1.

Fig. 1

Classification of neurological complications observed after COVID-19 vaccination

Neurological complications following COVID-19 vaccination

According to reports published in the VAERS database, COVID-19 vaccines have several local and systemic neurological complications that occur in different people, from mild to severe, depending on age, sex, history of the disease, and pre-existing immunity [7]. Complications usually appear within one day to 1 month after injection and are usually acute, transient, and self-limiting, but in severe cases lead to hospitalization and intensive care [8]. On the other hand, women have the highest incidence of neurological complications because they induce a stronger immune response against foreign antigens, which can lead to the targeting of self-antigens and lead to autoimmune disorders [9]. Adverse reactions after the second dose of the vaccine are reported more than in the first dose [5].

Mild neurological effects of the COVID-19 vaccine include weakness, numbness, headache, dizziness, imbalance, fatigue, muscle spasms, joint pain, and restless leg syndrome are more common, while tremors, tinnitus, and herpes zoster are less common. On the other hand, severe neurological complications included Bell's palsy, Guillain–Barre syndrome (GBS), stroke, seizures, anaphylaxis, and demyelinating syndromes such as transverse myelitis and acute encephalomyelitis [10]. Among these, the most dangerous neurological complication caused by COVID-19 vaccines, especially adenovirus-based, is cerebral venous sinus thrombosis in women of childbearing age [8].

According to the WHO, in the case of side effects of inactivated virus-based vaccines, especially Sinopharm, the most common local and systemic adverse reactions are injection site reactions, fatigue, fever, headache, and allergic dermatitis, which are self-limiting, and the person does not need to be hospitalized [11, 12]. It is noteworthy that rare and scattered reports have been published on the side effects of Sinopharm and other inactivated virus-based vaccines (Table 1). Vaccine reactivity has been linked to a temporary increase in inflammatory cytokines that act on blood vessels, muscles, and other tissues. In other words, we will observe the flu-like syndrome for several consecutive days after vaccination [13]. According to a recent report on the Sputnik vaccine, side effects are included headache, joint pain, fever, and flu-like symptoms [14]. According to published information on the side effects of other adenovirus vaccines, it is essential to properly evaluate the efficacy of the Sputnik vaccine and publish relevant data to decide on its side effects. COVID-19 vaccination can sometimes have severe side effects on nervous system, including the brain, spinal cord, cranial nerves, and peripheral nerves, and has been shown to have adverse vascular, metabolic, inflammatory, and functional effects on the brain [1].

Table 1 Reported neurological complications for inactivated virus-based vaccines

The two main mechanisms, ectopic immune reactions, and molecular mimicry, have been proposed for the pathogenicity of vaccines and how these complications occur.


The first and most common systemic side effect of COVID-19 vaccines is headache, which is mild to severe and is felt in the frontal area of the head. Post-vaccination headaches can be caused by stress, vascular spasm, and intracerebral or subarachnoid hemorrhage. Vaccines based on mRNA and adenovirus have been reported to be most likely to cause headaches [26].

Vascular complications in the brain

Due to the activity of the immune system, after the injection of COVID-19 vaccines, especially adenovirus-based type, thrombocytopenia, cerebral venous sinus thrombosis, ischemic stroke and intracerebral hemorrhage, have also been reported [27]. The proposed mechanism for thrombocytopenia is the synthesis of IgG antibodies against platelet factor 4 (PF4), which activates platelets and blood clots in large venous arteries [28]. Adenovirus-based vaccines are at the forefront of causing this complication due to the transfer of the nucleic acids encoding the viral spike (S) protein. Due to the leakage of these genetic materials and their binding to factor 4 platelet, autoimmunity develops [29]. Venous sinus thrombosis is associated with excessive coagulation. Vaccine viral antigens activate platelets or indirectly cause blood to clot by activating complement pathways and increasing thrombin production. Venous sinus thrombosis and cerebral hemorrhage are more common in women between the ages of 30 and 50 than in men (Table 2) [8].

Table 2 Reported neurological complications for adenovirus-based vaccines

Acute neurological disorders

These disorders include, transverse myelitis, acute diffuse encephalomyelitis (ADEM), Bell’s palsy, GBS, encephalopathy and seizures. Each type of vaccine can play a different role in increasing the risk of manifestation of these disorders (Tables 2, 3). The COVID-19 vaccine-related convulsions can be attributed to the synthesis and release of spike proteins, which cause severe inflammation and hyperthermia. Hyperthermia, in turn, increases glial cell activity and increases blood–brain barrier permeability. Following these events, as expected, peripheral blood cells and albumin enter the brain and disrupt the osmotic balance [10]. In connection with brain disorders, the possible mechanism is the entry of inflammatory mediators secreted by peripheral blood cells into the brain and the destruction of myelin and axonal degeneration. The presence of SARS-CoV-2 spike domain S1 antibodies in CSF may explain neurological complications after vaccination, such as encephalopathy and seizures [61].

Table 3 Reported neurological complications for mRNA-based vaccines

Transverse myelitis is an inflammation of a part of the spinal cord that usually occurs after infection and is associated with impaired sensory, motor, and autonomic function (bladder and intestines) in areas below the area of inflammation in the spinal cord. The mechanism of induction of this disorder is the development of autoimmunity by molecular mimicry. In fact, the viral antigens of the vaccine stimulate an immunological response in the spinal cord [62]. Transverse myelitis has been observed after injection of mRNA and adenovirus-based vaccines, and it is noteworthy that mRNA-based vaccines can cause exacerbation or early manifestation of MS and neuromyelitis optica. More generally, the majority of demyelinating syndromes are related to mRNA-based vaccines, followed by adenovirus-based vaccines. According to reports, these complications are more common in men and women between the ages of 20 and 60 [9].

COVID-19 vaccination also affects the cranial and peripheral nerves and causes side effects such as Bell's palsy (facial nerve palsy—7 cranial nerve), abducens nerve palsy (lateral rectus ocular muscle nerve palsy—6 cranial nerve), impaired vision, olfactory, hearing, Guillain–Barre syndrome (GBS), small fiber neuropathy, Parsonage–Turner syndrome, and also herpes zoster. In this case, too, the known mechanism is the induction of autoimmunity by molecular mimicry. Bell's palsy and small fiber neuropathy are more commonly observed in mRNA-based vaccines [63, 64]. GBS is also a peripheral nerves and nerve roots injury that presents with severe motor weakness and paralysis of the legs or four limbs and is more common in the elderly after vaccination with adenovirus-based vaccines [65]. There have been many reports of the Pfizer vaccine being associated with olfactory [66], visual [67], auditory [68, 69], and sometimes abducens nerve palsy. Olfactory dysfunction ranges from a lack of sense of smell to an olfactory hallucination (phantosmia) that results from a bilateral disturbance or enhancement of the olfactory pathway and the olfactory bulb. Hearing disorders can vary from hearing loss to tinnitus and dizziness. Also, there is ample evidence that the Pfizer and AstraZeneca vaccines are associated with optic nerve inflammation and vision disorders and are more common in middle-aged people [70].

Herpes zoster is a disease that occurs as a result of the reactivation of the varicella-zoster virus (VZV) after receiving the COVID-19 vaccine. The process that causes the disorder is probably explained by the fact that the varicella-zoster virus CD8+ killer cells, after vaccination, are temporarily unable to control VZV due to the extensive change of simple CD8+ cells to the COVID-19 virus CD8+ killer cells. Therefore, vaccination is like a shock to the recurrence of VZV and subsequent herpes zoster [71]. mRNA-based vaccines can increase the risk of herpes zoster [72]. There was a recent report of Ramsey Hunt Syndrome (RHS after the Pfizer vaccination. RHS leads to facial nerve palsy, vestibulocochlear neuropathy, and glossopharyngeal nerve neuropathy, so it causes numbness of the face, tongue, and hearing loss. In addition, skin blisters have been observed in the ear area, leading us to hypothesize that reactivation of VZV could be a cause for RHS as well as Bell's palsy [71].


According to the vaccine study literature, adverse effects have always been part of the mass vaccination strategy, but ultimately the desired effects of the vaccination are more significant. Side effects of COVID-19 vaccination have been reported more frequently in people with a history of immune-related diseases or who are more sensitive to age and physiological conditions. The most important and most common complications are cerebral venous sinus thrombosis (more about AstraZeneca), transverse myelitis (more about Pfizer, Moderna, AstraZeneca, and Johnson & Johnson), Bell's palsy (more about Pfizer, Moderna, AstraZeneca), GBS (more about Pfizer, AstraZeneca, and Johnson & Johnson), and the first manifestation of MS (more about Pfizer). Finally, discovering whether these disorders are accidental or whether the vaccine is the main cause of them requires future studies, ongoing efforts to gather evidence, and long-term monitoring.


  1. Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2021. ArticlePubMedPubMed Central Google Scholar

  2. Accessed 13 Novr 2022

  3. Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021;19:2508–17. ArticleCASPubMedPubMed Central Google Scholar

  4. Abraham G, Bhalala OG, de Bakker PI, Ripatti S, Inouye M. Towards a molecular systems model of coronary artery disease. Curr Cardiol Rep. 2014;16(6):1–10. Article Google Scholar

  5. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, Shaban D, Al Khames Aga LA, Agha MY, Traqchi M. Safety of COVID-19 vaccines. J Med Virol. 2021;93(12):6588–94. ArticleCASPubMedPubMed Central Google Scholar

  6. Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13(3):215–24. ArticlePubMed Google Scholar

  7. Dutta S, Kaur R, Charan J, Bhardwaj P, Ambwani SR, Babu S, Goyal JP, Haque M. Analysis of neurological adverse events reported in VigiBase from COVID-19 vaccines. Cureus. 2022. ArticlePubMedPubMed Central Google Scholar

  8. Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand. 2022;145(1):5–9. ArticleCASPubMed Google Scholar

  9. Ismail II, Salama S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2022;362: 577765. ArticleCASPubMed Google Scholar

  10. Assiri SA, Althaqafi RM, Alswat K, Alghamdi AA, Alomairi NE, Nemenqani DM, Ibrahim ZS, Elkady A. Post COVID-19 vaccination-associated neurological complications. Neuropsychiatr Dis Treat. 2022;18:137. ArticleCASPubMedPubMed Central Google Scholar

  11. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, Jahantigh HR. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathologia Persa. 2021;7(2):31. Article Google Scholar

  12. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219–26. ArticleCASPubMedPubMed Central Google Scholar

  13. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. ArticleCASPubMed Google Scholar

  14. Kadyrova I, Yegorov S, Negmetzhanov B, Kolesnikova Y, Kolesnichenko S, Korshukov I, Baiken Y, Matkarimov B, Miller MS, Hortelano GH. Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. medRxiv. 2022. Article Google Scholar

  15. Cao L, Ren L. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. Acta Neurol Belg. 2021;122(3):793–5. ArticlePubMedPubMed Central Google Scholar

  16. Erdem NŞ, Demirci S, Özel T, Mamadova K, Karaali K, Çelik HT, Uslu FI, Özkaynak SS. Acute transverse myelitis after inactivated COVID-19 vaccine. Ideggyogyaszati Szemle. 2021;74(7–08):273–6. ArticlePubMed Google Scholar

  17. Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. J Neurol. 2021;269(3):1121–32. ArticlePubMedPubMed Central Google Scholar

  18. Malhotra HS, Gupta P, Prabhu V, Garg RK, Dandu H, Agarwal V. COVID-19 vaccination-associated myelitis. QJM: An Int J Med. 2021. Article Google Scholar

  19. Corrêa DG, Cañete LAQ, Dos Santos GAC, de Oliveira RV, Brandão CO, da Cruz Jr LCH. Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? Clin Imaging. 2021;80:348–52. ArticlePubMedPubMed Central Google Scholar

  20. Ozgen Kenangil G, Ari BC, Guler C, Demir MK. Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine. Acta Neurol Belg. 2021;121(4):1089–91. ArticlePubMedPubMed Central Google Scholar

  21. Chen S, Fan X-R, He S, Zhang J-W, Li S-J. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol Sci. 2021;42(9):3537–9. ArticlePubMedPubMed Central Google Scholar

  22. Seyed Ahadi M, Ghadiri F, Naser Moghadasi A. Acute attack in a patient with multiple sclerosis 2 days after COVID vaccination: a case report. Acta Neurol Belg. 2021. ArticlePubMedPubMed Central Google Scholar

  23. Burrows A, Bartholomew T, Rudd J, Walker D. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Reports CP. 2021;14(7): e243829. Article Google Scholar

  24. Ercoli T, Lutzoni L, Orofino G, Muroni A, Defazio G. Functional neurological disorder after COVID-19 vaccination. Neurol Sci. 2021;42(10):3989–90. ArticlePubMedPubMed Central Google Scholar

  25. Ish S, Ish P. Facial nerve palsy after COVID-19 vaccination–A rare association or a coincidence. Indian J Ophthalmol. 2021;69(9):2550. ArticlePubMedPubMed Central Google Scholar

  26. Ekizoglu E, Gezegen H, Yalınay Dikmen P, Orhan EK, Ertaş M, Baykan B (2021) The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic. Cephalalgia. 42(4–5):366–75. PubMedPubMed Central Google Scholar

  27. Schulz JB, Berlit P, Diener HC, Gerloff C, Greinacher A, Klein C, Petzold GC, Piccininni M, Poli S, Röhrig R. COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann Neurol. 2021;90(4):627–39. ArticleCASPubMedPubMed Central Google Scholar

  28. Iba T, Levy JH, Warkentin TE. Recognizing vaccine-induced immune thrombotic thrombocytopenia. Crit Care Med. 2022;50(1): e80. ArticleCASPubMed Google Scholar

  29. McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun. 2021;121: 102662. ArticleCASPubMedPubMed Central Google Scholar

  30. Bourguignon A, Arnold DM, Warkentin TE, Smith JW, Pannu T, Shrum JM, Al Maqrashi ZA, Shroff A, Lessard M-C, Blais N. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. New Engl J Med. 2021;385(8):720–8. ArticleCASPubMed Google Scholar

  31. Clark RT, Johnson L, Billotti J, Foulds G, Ketels T, Heard K, Hynes EC. Early outcomes of bivalirudin therapy for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after Ad26. COV2.S vaccination. Ann Emergency Med. 2021;78(4):511–4. Article Google Scholar

  32. D’agostino V, Caranci F, Negro A, Piscitelli V, Tuccillo B, Fasano F, Sirabella G, Marano I, Granata V, Grassi R. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration. J Personal Med. 2021;11(4):285. Article Google Scholar

  33. Franchini M, Testa S, Pezzo M, Glingani C, Caruso B, Terenziani I, Pognani C, Bellometti SA, Castelli G. Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination. Thromb Res. 2021;202:182–3. ArticleCASPubMedPubMed Central Google Scholar

  34. García-Azorín D, Do TP, Gantenbein AR, Hansen JM, Souza MNP, Obermann M, Pohl H, Schankin CJ, Schytz HW, Sinclair A. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. J Headache Pain. 2021;22(1):1–5. Article Google Scholar

  35. George G, Friedman KD, Curtis BR, Lind SE. Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26. COV2. S vaccination. Am J Hematol. 2021;96(8):E301–3. ArticleCASPubMed Google Scholar

  36. Ramdeny S, Lang A, Al-Izzi S, Hung A, Anwar I, Kumar P. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT). Br J Haematol. 2021. ArticlePubMedPubMed Central Google Scholar

  37. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. New Engl J Med. 2021;384(23):2202–11. ArticleCASPubMed Google Scholar

  38. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci. 2021;428: 117607. ArticleCASPubMedPubMed Central Google Scholar

  39. Gao J-J, Tseng H-P, Lin C-L, Shiu J-S, Lee M-H, Liu C-H. Acute transverse myelitis following COVID-19 vaccination. Vaccines. 2021;9(9):1008. ArticleCASPubMedPubMed Central Google Scholar

  40. Notghi AA, Atley J, Silva M. Lessons of the month 1: Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination. Clin Med (Northfield Il). 2021;21(5): e535. Article Google Scholar

  41. Pagenkopf C, Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol. 2021;358: 577606. ArticleCASPubMedPubMed Central Google Scholar

  42. Tahir N, Koorapati G, Prasad S, Jeelani HM, Sherchan R, Shrestha J, Shayuk M. SARS-CoV-2 vaccination-induced transverse myelitis. Cureus. 2021. ArticlePubMedPubMed Central Google Scholar

  43. Vegezzi E, Ravaglia S, Buongarzone G, Bini P, Diamanti L, Gastaldi M, Prunetti P, Rognone E, Marchioni E. Acute myelitis and ChAdOx1 nCoV-19 vaccine: casual or causal association? J Neuroimmunol. 2021;359: 577686. ArticleCASPubMedPubMed Central Google Scholar

  44. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99–111. ArticleCAS Google Scholar

  45. Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, Evans JR. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021;90(2):315–8. ArticleCASPubMed Google Scholar

  46. Bonifacio GB, Patel D, Cook S, Purcaru E, Couzins M, Domjan J, Ryan S, Alareed A, Tuohy O, Slaght S. Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine. J Neurol Neurosurg Psychiatry. 2021. ArticlePubMed Google Scholar

  47. Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Reports CP. 2021;14(6): e243629. Article Google Scholar

  48. Kohli S, Varshney M, Mangla S, Jaiswal B, Chhabra PH. Guillain-Barré syndrome after COVID-19 vaccine: should we assume a causal Link? Int J Med Pharm Case Rep: 20-24. 2021. Article Google Scholar

  49. Permezel F, Borojevic B, Lau S, de Boer HH. Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination. Forensic Sci Med Pathol. 2021. ArticlePubMedPubMed Central Google Scholar

  50. Bjørnstad-Tuveng TH, Rudjord A, Anker P. Fatal cerebral haemorrhage after COVID-19 vaccine. Tidsskrift for Den norske legeforening. 2021. ArticlePubMed Google Scholar

  51. Baldelli L, Amore G, Montini A, Panzera I, Rossi S, Cortelli P, Guarino M, Rinaldi R, D’Angelo R. Hyperacute reversible encephalopathy related to cytokine storm following COVID-19 vaccine. J Neuroimmunol. 2021;358: 577661. ArticleCASPubMedPubMed Central Google Scholar

  52. Antonio Crespo Burillo J, Martínez CL, Arguedas CG, Pueyo FJM. Amyotrophic neuralgia secondary to Vaxzevria (AstraZeneca) COVID-19 vaccine. Neurologia (Barc, Ed impr). 2021. Article Google Scholar

  53. Alpalhão M, Filipe P. Herpes Zoster following SARS-CoV-2 vaccination–a series of four cases. J Eur Acad Dermatol Venereol. 2021. ArticlePubMedPubMed Central Google Scholar

  54. Tseng P-T, Chen T-Y, Sun Y-S, Chen Y-W, Chen J-J. The reversible tinnitus and cochleopathy followed first-dose AstraZeneca COVID-19 vaccination. QJM An Int J Med. 2021. Article Google Scholar

  55. Finsterer J, Scorza FA, Scorza CA. Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients. Clinics. 2021. ArticlePubMedPubMed Central Google Scholar

  56. Introna A, Caputo F, Santoro C, Guerra T, Ucci M, Mezzapesa DM, Trojano M. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: a causal or casual association? Clin Neurol Neurosurg. 2021;208: 106887. ArticlePubMedPubMed Central Google Scholar

  57. Jain E, Pandav K, Regmi P, Michel G, Altshuler I. Facial diplegia: a rare, atypical variant of Guillain-Barré syndrome and Ad26. COV2. S Vaccine. Cureus. 2021. ArticlePubMedPubMed Central Google Scholar

  58. Loza AMM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology. 2021;96(22):1052–4. Article Google Scholar

  59. Malik B, Kalantary A, Rikabi K, Kunadi A. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. BMJ Case Reports CP. 2021;14(7): e243975. Article Google Scholar

  60. Etemadifar M, Sigari AA, Sedaghat N, Salari M, Nouri H. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. Hum Vaccin Immunother. 2021;17(10):3481–3. ArticleCASPubMedPubMed Central Google Scholar

  61. Fan H-T, Lin Y-Y, Chiang W-F, Lin C-Y, Chen M-H, Wu K-A, Chan J-S, Kao Y-H, Shyu H-Y, Hsiao P-J. COVID-19 vaccine-induced encephalitis and status epilepticus. QJM: An Int J Med. 2022. Article Google Scholar

  62. Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021;12:879. Article Google Scholar

  63. Ozonoff A, Nanishi E, Levy O. Bell’s palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021;21(4):450–2. ArticleCASPubMedPubMed Central Google Scholar

  64. Waheed W, Carey ME, Tandan SR, Tandan R. Post COVID-19 vaccine small fiber neuropathy. Muscle Nerve. 2021;64(1):E1. ArticleCASPubMedPubMed Central Google Scholar

  65. Dyer O. Covid-19: Regulators warn that rare Guillain-Barré cases may link to J&J and AstraZeneca vaccines. Br Med J Publ Gr. 2021. Article Google Scholar

  66. Keir G, Maria NI, Kirsch CF. Unique imaging findings of neurologic phantosmia following Pfizer-BioNtech COVID-19 vaccination: a case report. Top Magn Reson Imaging. 2021;30(3):133–7. ArticlePubMed Google Scholar

  67. Santovito LS, Pinna G. Acute reduction of visual acuity and visual field after Pfizer-BioNTech COVID-19 vaccine 2nd dose: a case report. Inflammation Res. 2021;70(9):931–3. ArticleCAS Google Scholar

  68. Parrino D, Frosolini A, Gallo C, De Siati RD, Spinato G, de Filippis C. Tinnitus following COVID-19 vaccination: report of three cases. Int J Audiol. 2021. ArticlePubMed Google Scholar

  69. Wichova H, Miller ME, Derebery MJ. Otologic manifestations after COVID-19 vaccination: the house ear clinic experience. Otol Neurotol. 2021;42(9): e1213. ArticlePubMedPubMed Central Google Scholar

  70. Žorić L, Rajović-Mrkić I, Čolak E, Mirić D, Kisić B. Optic neuritis in a patient with seropositive myelin oligodendrocyte glycoprotein antibody during the post-COVID-19 period. Int Med Case Rep J. 2021;14:349. ArticlePubMedPubMed Central Google Scholar

  71. Woo CJ, Chou OHI, Cheung BMY. Ramsay Hunt syndrome following COVID-19 vaccination. Postgrad Med J. 2022. ArticlePubMed Google Scholar

  72. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, Desai SR, French LE, Lim HW, Thiers BH. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. ArticleCASPubMedPubMed Central Google Scholar

  73. Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, Hamid Q, Halwani R, Temsah M-H, Ziemann M. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun. 2021;3(3):169. Article Google Scholar

  74. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396(10267):1979–93. ArticleCAS Google Scholar

  75. Havla J, Schultz Y, Zimmermann H, Hohlfeld R, Danek A, Kümpfel T. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neurol. 2022;269(1):55–8. ArticleCASPubMed Google Scholar

  76. Khayat-Khoei M, Bhattacharyya S, Katz J, Harrison D, Tauhid S, Bruso P, Houtchens MK, Edwards KR, Bakshi R. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol. 2021. ArticlePubMedPubMed Central Google Scholar

  77. Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021;9(5):435. ArticleCASPubMedPubMed Central Google Scholar

  78. Alshararni A. Acute transverse myelitis associated with COVID-19 vaccine: a case report. Int J Res Pharma Sci. 2021;12:2083–7. ArticleCAS Google Scholar

  79. McLean P, Trefts L. Transverse myelitis 48 hours after the administration of an mRNA COVID 19 vaccine. Neuroimmunology Reports. 2021;1: 100019. ArticleCASPubMed Central Google Scholar

  80. Finsterer J. Exacerbating Guillain-Barré Syndrome Eight Days after vector-based COVID-19 vaccination. Case Rep Infect Dis. 2021. ArticlePubMedPubMed Central Google Scholar

  81. Ogbebor O, Seth H, Min Z, Bhanot N. Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: a temporal occurrence, not a causal association. IDCases. 2021;24: e01143. ArticleCASPubMedPubMed Central Google Scholar

  82. Razok A, Shams A, Almeer A, Zahid M. Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar. Ann Med Surg. 2021;67: 102540. Article Google Scholar

  83. Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021. ArticlePubMedPubMed Central Google Scholar

  84. de Terreros Caro GG, Díaz SG, Alé MP, Gimeno MM. Bell’s palsy following COVID-19 vaccination: a case report. Neurologia (Barcelona, Spain). 2021. Article Google Scholar

  85. Obermann M, Krasniqi M, Ewers N, Fayad J, Haeberle U. Bell’s palsy following COVID-19 vaccination with high CSF antibody response. Neurol Sci. 2021;42(11):4397–9. ArticlePubMedPubMed Central Google Scholar

  86. Repajic M, Lai XL, Xu P, Liu A. Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. Brain Behav Immun Health. 2021;13: 100217. ArticleCASPubMedPubMed Central Google Scholar

  87. Vogrig A, Janes F, Gigli GL, Curcio F, Del Negro I, D’Agostini S, Fabris M, Valente M. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin Neurol Neurosurg. 2021;208: 106839. ArticlePubMedPubMed Central Google Scholar

  88. Konstantinidis I, Tsakiropoulou E, Hähner A, de With K, Poulas K, Hummel T. Olfactory dysfunction after coronavirus disease 2019 (COVID-19) vaccination. Int Forum Allergy Rhinol. 2021. ArticlePubMedPubMed Central Google Scholar

  89. Ahmed SH, Waseem S, Shaikh TG, Qadir NA, Siddiqui SA, Ullah I, Waris A, Yousaf Z. SARS-CoV-2 vaccine-associated-tinnitus: a review. Ann Med Surg. 2022;75:103293. Article Google Scholar

  90. Reyes-Capo DP, Stevens SM, Cavuoto KM. Acute abducens nerve palsy following COVID-19 vaccination. J Am Assoc Pediatr Ophthalmol Strabismus. 2021;25(5):302–3. Article Google Scholar

  91. Chiu H-H, Wei K-C, Chen A, Wang W-H. Herpes zoster following COVID-19 vaccine: a report of three cases. QJM: An Int J Med. 2021;114(7):531–2. ArticleCAS Google Scholar

  92. Rodríguez-Jiménez P, Chicharro P, Cabrera L-M, Seguí M, Morales-Caballero Á, Llamas-Velasco M, Sánchez-Pérez J. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep. 2021;12:58–9. ArticlePubMedPubMed Central Google Scholar

  93. Salinas MR, Dieppa M. Transient akathisia after the SARS-Cov-2 vaccine. Clin Park Relat Disord. 2021;4: 100098. PubMedPubMed Central Google Scholar

  94. Finsterer J, Redzic Z. Symptomatic peduncular, cavernous bleeding following SARS-CoV-2 vaccination induced immune thrombocytopenia. Brain Hemorrhages. 2021;2(4):169–71. ArticleCASPubMedPubMed Central Google Scholar

  95. Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost. 2021;19(7):1771–5. ArticleCASPubMed Google Scholar

  96. Fitzsimmons W, Nance CS. Sudden onset of myelitis after COVID-19 vaccination: an under-recognized severe rare adverse event. SSRN. 2021. Article Google Scholar

  97. Martin-Villares C, Vazquez-Feito A, Gonzalez-Gimeno M, de la Nogal-Fernandez B. Bell’s palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report. J Neurol. 2022;269(1):47–8. ArticleCASPubMed Google Scholar

  98. Al-Mashdali AF, Ata YM, Sadik N. Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: a case report. Ann Med Surg. 2021;69: 102803. Article Google Scholar

  99. Channa L, Torre K, Rothe M. Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination. JAAD Case Rep. 2021;15:60–1. ArticlePubMedPubMed Central Google Scholar

  100. Liu BD, Ugolini C, Jha P. Two cases of post-Moderna COVID-19 vaccine encephalopathy associated with nonconvulsive status epilepticus. Cureus. 2021. ArticlePubMedPubMed Central Google Scholar

  101. Šín R, Štruncová D. Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: a case report. World J Clin Cases. 2021;9(24):7218. ArticlePubMedPubMed Central Google Scholar

  102. Athyros VG, Doumas M. A possible case of hypertensive crisis with intracranial haemorrhage after an mRNA anti-COVID-19 vaccine. Angiology. 2022;73(1):87–87.

13 views0 comments


bottom of page